trending Market Intelligence /marketintelligence/en/news-insights/trending/gz58bkvgpbxh_qpllu5_za2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US FDA grants Lupin tentative approval to market generic ulcer drug

Cable Net Valuation Benchmarks Hit Recent Low In CBS-Viacom Deal

US Smart Cities Projects To Push Annual Revenue Over 700 Million In Five-Year Outlook

Panjiva Insights: The Global Trade War’s Impact and Road Ahead

MI Mobile App


US FDA grants Lupin tentative approval to market generic ulcer drug

The U.S. FDA granted Lupin Ltd. tentative approval to market its balasalazide disodium tablets, a generic version of Salix Pharmaceutical Inc.'s Giazo.

The drug is meant for the treatment of ulcerative colitis in male patients above the age of 18 years.